Gritstone Bio has reported positive results from the first cohort of Phase I CORAL-BOOST clinical trial of its CORAL self-amplifying mRNA (samRNA) vaccine for Covid-19.

Findings showed that the 10µg vaccine dose offered robust neutralising antibody responses to Spike and strong CD8+ T cell responses.

One of four trials of the CORAL programme, CORAL-BOOST is assessing the reactogenicity, safety and immunogenicity of the vaccine directed against Spike and highly conserved non-Spike T cell epitopes (TCE) as a Covid-19 booster shot.

This ongoing trial in the UK enrolled healthy adult subjects aged 60 years or above and were vaccinated with two doses of AstraZeneca‘s AZD1222 (Vaxzevria) Covid-19 vaccine.

New CD8+ T cell responses across a wide range of non-spike epitopes, including several established T cell targets, were observed in the trial, which indicates the vaccine’s variant-proof immunity potential.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The vaccine was also found to be well-tolerated in the trial.

It also showed an encouraging safety profile without any grade 3/4 side effects or unexpected reactogenicity or safety issues noted in ten healthy trial adult subjects.

Gritstone bio co-founder, president and CEO Andrew Allen said: “We designed our Covid-19 vaccines to drive broad CD8+ T cell immunity, an additional key layer of protection against viruses.

“This innovation enables the inclusion of a wide array of highly conserved viral epitopes, potentially creating an immune state that may offer more robust clinical protection against current and future SARS-CoV-2 variants and be a first step toward developing a pan-coronavirus vaccine.”

Presently, the trial dose-escalated to a 30mg dose of the vaccine.

With the latest development, the company is modifying the trial to raise the subject enrolment to 120 and assess the inclusion of a second samRNA-Spike-TCE dose of the shot.

Last September, Gritstone dosed the first subjects in a Phase I trial of a self-amplifying mRNA Covid-19 vaccine.